Female physicians associated with improved inpatient mortality and readmission rates
1. In this observational study, inpatients treated by a female physician had lower 30-day...
Read MoreMay 21, 2024
1. In this observational study, inpatients treated by a female physician had lower 30-day...
Read MoreMay 21, 2024
1. A decision support system using the Molecular International Prognostic Scoring System (IPSS-M)...
Read MoreMay 18, 2024
1. Consumption of ultra-processed foods was associated with modestly higher all cause mortality,...
Read MoreMay 17, 2024
1. At 12 months, patients with anterior cruciate ligament reconstruction randomized to receive...
Read MoreMay 15, 2024
1. 3-year invasive disease-free survival among the PET-based treatment group was 94.8%. 2. There...
Read MoreMay 15, 2024
1. Among patients on anticancer treatment with malignancy who were 75 years of age or older, the...
Read MoreMay 14, 2024
1. Although capecitabine or XELOX did not improve overall survival when compared to PF, efficacy...
Read MoreMay 14, 2024
1. The objective response rate for trastuzumab deruxtecan was 29.4%. 2. Treatment-emergent adverse...
Read MoreMay 14, 2024
1. Achieving Minimal Residual Disease (MRD) negativity at baseline before lenalidomide...
Read MoreMay 14, 2024
1. The use of recombinant L-IFN adenovirus in patients with recurrent or refractory advanced solid...
Read MoreMay 13, 2024
1. Increased incidence of radiographic knee osteoarthritis was associated with high amounts of...
Read MoreMay 13, 2024
1. In a cohort of men with prostate cancer, disease progression was lower in men who had a higher...
Read MoreMay 7, 2024
1. Lymphoid malignancy survival rates in European countries correlate with natation health...
Read MoreMay 6, 2024
1. In this cohort study, individual and area level social determinants of health (SDOH) were...
Read MoreMay 5, 2024
1. In a cohort of individuals, those diagnosed with an opioid use disorder (OUD), anxiety, or...
Read MoreMay 4, 2024
1. In a cohort study in South Korea, prenatal opioid use did not significantly increase the risk...
Read MoreMay 2, 2024
1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events...
Read MoreMay 1, 2024
1. Progression-free survival at 24 months was higher in the pembrolizumab versus...
Read MoreApr 30, 2024
1. For patients with localized endometrial cancer recurrence, adding cisplatin to radiation...
Read MoreApr 30, 2024
1. The median overall survival was 17.6 months in the gefitinib group vs 27.5 months in the...
Read More